Creative Planning Intellia Therapeutics, Inc. Transaction History

Creative Planning

$106 Billion
Q1 2025

A detailed history of Creative Planning transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Creative Planning holds 29,307 shares of NTLA stock, worth $273,141. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,307

Previous 21,163 38.48%

Holding current value

$273,141

Previous $246,000 15.45%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$7.11 - $12.8 $57,903 - $104,243	8,144 Added 38.48%	29,307 $208,000
Q4 2024 Feb 14, 2025	BUY	$11.41 - $21.09 $98,331 - $181,753	8,618 Added 68.7%	21,163 $246,000
Q3 2024 Oct 11, 2024	BUY	$19.72 - $27.36 $4,160 - $5,772	211 Added 1.71%	12,545 $257,000
Q2 2024 Aug 15, 2024	SELL	$20.02 - $27.22 $101,981 - $138,658	-5,094 Reduced 29.23%	12,334 $276,000
Q1 2024 May 10, 2024	BUY	$23.82 - $32.8 $201,421 - $277,356	8,456 Added 94.25%	17,428 $479,000
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $202,812 - $283,201	8,757 Added 4073.02%	8,972 $273,000
Q3 2023 Nov 16, 2023	BUY	$31.62 - $45.78 $6,798 - $9,842	215 New	215 $6,000
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $8,275 - $16,385	-215 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $12,528 - $25,582	215 New	215 $16,000
Q4 2021 Feb 11, 2022	SELL	$100.76 - $138.36 $182,375 - $250,431	-1,810 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$132.37 - $176.78 $239,589 - $319,971	1,810 New	1,810 $243,000
Q2 2020 Jul 23, 2020	SELL	$11.14 - $22.87 $708,069 - $1.45 Million	-63,561 Closed	0 $0
Q1 2020 May 05, 2020	SELL	$9.44 - $15.58 $192,132 - $317,099	-20,353 Reduced 24.25%	63,561 $777,000
Q4 2019 Jan 30, 2020	BUY	$10.43 - $17.67 $4,182 - $7,085	401 Added 0.48%	83,914 $1.23 Million
Q3 2019 Nov 01, 2019	SELL	$13.07 - $18.51 $7,972 - $11,291	-610 Reduced 0.73%	83,513 $1.12 Million
Q2 2019 Jul 26, 2019	BUY	$13.88 - $18.41 $84,668 - $112,301	6,100 Added 7.82%	84,123 $1.38 Million
Q1 2019 Apr 24, 2019	BUY	$12.79 - $17.62 $6,279 - $8,651	491 Added 0.63%	78,023 $1.33 Million
Q4 2018 Feb 01, 2019	SELL	$11.39 - $27.13 $4,089 - $9,739	-359 Reduced 0.46%	77,532 $1.06 Million
Q3 2018 Oct 25, 2018	SELL	$25.78 - $32.6 $12,090 - $15,289	-469 Reduced 0.6%	77,891 $2.23 Million
Q2 2018 Jul 20, 2018	BUY	$20.02 - $30.79 $589,188 - $906,149	29,430 Added 60.15%	78,360 $2.14 Million
Q1 2018 Apr 18, 2018	BUY	$19.43 - $34.95 $9,326 - $16,776	480 Added 0.99%	48,930 $1.03 Million
Q4 2017 Jan 17, 2018	BUY	$17.39 - $31.12 $644,038 - $1.15 Million	37,035 Added 324.44%	48,450 $931,000
Q3 2017 Oct 17, 2017	BUY	$15.16 - $25.75 $173,051 - $293,936	11,415	11,415 $284,000

Others Institutions Holding NTLA

# of Institutions

344

Shares Held

98.4M

Call Options Held

784K

Put Options Held

713K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $708M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Account

Creative Planning Intellia Therapeutics, Inc. Transaction History